Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is a promising investment opportunity due to its strong partnership with Regeneron Pharmaceuticals, which provides external validation of its capabilities, and its robust financial performance, with revenues of $230MM in 1Q26, ahead of expected estimates. Additionally, Telix's multiple clinical inflection points and advancements in its pipeline, including enrollment in pivotal studies and potential data readouts in the near future, make it a strong player in the radiopharmaceutical market.

Bears say

Telix Pharmaceuticals is a company that has seen success in their current revenue streams from the sales of Illuccix in the US, but their future potential for growth is dependent on the success of their pipeline of radiopharmaceutical drugs. While their partnership with Regeneron provides non-dilutive capital and potential long term upside, there is a significant risk of clinical and regulatory failures that could impact their future sales estimates and ultimately their stock price. Their current valuation and risks suggest that there is limited potential for growth, resulting in a negative outlook for the stock.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.